Cardiac Arrhythmia Represents Dangerous Side Effect of Anzemet – Anti-Nausea Drug for Chemotherapy Patients

Late last year, the FDA issued a warning against the use of the injectable form of dolasetron mesylate (Anzemet) to prevent nausea and vomiting in patients undergoing cancer chemotherapy in light of new data indicating the drug can cause life-threatening cardiac arrhythmias. The FDA indicated that Anzemet may still be given orally to chemotherapy patients, or injected at lower doses following surgery to prevent postoperative nausea and vomiting.

Patients at particular risk from Anzemet are those with underlying heart conditions or those who have existing heart rate or rhythm problems.

About the Author

Tom D'Amore is the founder of D'Amore Law Group and a trial attorney with over 30 years of experience representing injured people and their families across the West Coast, securing more than $325 million in recoveries. He handles cases involving car accidents, trucking accidents, construction injuries, medical malpractice, and sexual abuse. Licensed in Oregon, Washington, and California, Tom is the only NBTA board-certified truck accident attorney in Oregon. He is a national Board of Governors member, past Executive Committee member, and past Budget and Audit Chair of the American Association for Justice, as well as past President of the Oregon Trial Lawyers Association and an Eagle member of the Washington State Association for Justice.